Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Journal subject
Affiliation country
Publication year range
1.
Expert Opin Pharmacother ; 24(9): 1067-1073, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37128968

ABSTRACT

INTRODUCTION: Endometriosis is a benign chronic inflammatory disease responsible for debilitating pain and decreased quality of life. The traditional treatment is based on estroprogestins, progestins, GnRH analogs, and surgery. Recently, aromatase inhibitors (AIs) demonstrated good efficacy in controlling symptoms and size of endometriotic implants, mostly because they suppress extraovarian estrogen synthesis, which can enhance the hypoestrogenic state ameliorating symptoms of endometriosis. AREAS COVERED: Phase I, II, III and IV trials, on the use of AIs used for the treatment of endometriosis, have been retrieved. The pharmacokinetics and pharmacodynamics of third-generation non-steroidal AIs have also been investigated. A MEDLINE search has been performed using the following MeSH keywords: 'endometriosis,' aromatase inhibitors,' 'therapy,' and 'treatment'. The timeframe was from 2010 up to November 2022 including reviews, systematic reviews, reports, case series, and retrospective or prospective trials. EXPERT OPINION: AIs have shown good clinical efficacy in combination with hormonal therapy in disease control, and they represent a promising second-line therapy in selected patients, yet more research is needed on alternative drug delivery systems and better control of adverse effects. In postmenopausal women in which surgery is contraindicated, AIs represent an excellent treatment option. Their application in routine clinical practice remains limited by adverse effects.


Subject(s)
Aromatase Inhibitors , Endometriosis , Humans , Female , Aromatase Inhibitors/adverse effects , Endometriosis/drug therapy , Quality of Life , Prospective Studies , Retrospective Studies
2.
Doc Ophthalmol ; 107(2): 111-4, 2003 Sep.
Article in English | MEDLINE | ID: mdl-14661900

ABSTRACT

The authors describe their findings on 12 subjects who were treated with 50 mg of sildenafil (Viagra) and underwent ERG measurements prior to and 1 hour after ingestion. The Naka-Rushton equation was used to describe the b-wave luminance-response function of the scotopic ERG. Statistically significant differences were noted in the Vmax and K values. Sildenafil ingestion resulted in an increase in Vmax (higher rod response to light stimuli) and a decrease in K (higher sensitivity).


Subject(s)
Erectile Dysfunction/drug therapy , Erectile Dysfunction/physiopathology , Phosphodiesterase Inhibitors/adverse effects , Piperazines/adverse effects , Retina/drug effects , Retina/physiopathology , Electroretinography , Humans , Male , Middle Aged , Purines , Sildenafil Citrate , Sulfones , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL